2023 Meeting Magazine - 40

INDUSTRY EVENTS
Innovation
Theaters
Innovation Theater sessions are industry-supported, non-CME events held in two theaters in Booth 937 in the Exhibit
Hall. Some sessions are also livestreamed in the sponsor's exhibit booth, as noted in the schedule below. The schedule
is accurate as of October 13, 2023, and subject to change. Download the ACR Convergence App for the most up-to-date
meeting information.
Theater A
SUNDAY, NOVEMBER 12
10:30-11:15 a.m.
nr-axSpA: BREAKING THE CODE
UCB, Inc. (Session is also livestreaming to exhibit booth)
12:30-1:15 p.m.
SAPHNELO®
(anifrolumab-fnia): A First-In-Class
IFN-1 Signaling Inhibitor, Now With 4-Year Data
From a Long-Term Safety and Tolerability Study
AstraZeneca (Session is also livestreaming to exhibit booth)
2:30-3:15 p.m.
The First FDA-Approved Biologic for the Treatment
of Polymyalgia Rheumatica: A Deep Dive
Sanofi (Session is also livestreaming to exhibit booth)
MONDAY, NOVEMBER 13
10:30-11:15 a.m.
Use of a Prescription Janus Kinase (JAK) Inhibitor for
Active Ankylosing Spondylitis (AS), Including Review
of a Hypothetical Patient Case
Pfizer, Inc. (Session is also livestreaming to exhibit booth)
12:30-1:15 p.m.
Autoimmune-Associated Interstitial Lung Disease:
A Patient's Journey, A Physician's Perspective, and
the Power of Collaborative Care
Boehringer Ingelheim Pharmaceuticals, Inc.
2:30-3:15 p.m.
A Clinical Approach to Hypophosphatasia
Alexion
TUESDAY, NOVEMBER 14
10:30-11:15 a.m.
Holistic Care of the Immunocompromised Rheumatologic
Patient - Case Analysis
GSK
12:30-1:15 p.m.
Pioneering CAR T Cell Therapy in Autoimmune Diseases:
A Fireside Chat with Dr. Georg Schett and Dr. Carl June
Cabaletta Bio
ACR CONVERGENCE 2023
40
Theater B
SUNDAY, NOVEMBER 12
11:30 a.m.-12:15 p.m.
Treating Patients with PsA and AS Today & Tomorrow
Eli Lilly and Company
1:30-2:15 p.m.
Updated Guidance Calls for the Earlier Use of Biologics:
Are You Embracing the Change?
GSK (Session is also livestreaming to exhibit booth)
3:30-4:15 p.m.
Expert Perspectives: Identification and Management
of Eosinophilic Granulomatosis with Polyangiitis
GSK
MONDAY, NOVEMBER 13
11:30 a.m.-12:15 p.m.
COSENTYX®
1:30-2:15 p.m.
TREMFYA®
(secukinumab) Joint Decision Making
Novartis Pharmaceuticals Corporation
Efficacy, Safety, and Real-World Evidence
with Subtitle: in Adults with Active Psoriatic Arthritis
Janssen
3:30-4:15 p.m.
Breaking the Cycle of Recurrent Pericarditis: A Targeted
Approach for Pain Relief, Inflammation Resolution, and Flare
Prevention
Kiniksa Pharmaceuticals Corp
TUESDAY, NOVEMBER 14
11:30 a.m.-12:15 p.m.
A Rheumatologist and Nephrologist Discuss Kidney
Preservation in Lupus Nephritis
Aurinia Pharma U.S.
1:30-2:15 p.m.
The Inflammatory Role of the Eosinophil in EGPA
AstraZeneca

2023 Meeting Magazine

Table of Contents for the Digital Edition of 2023 Meeting Magazine